Market Research Logo

Global Infantile Spasms Therapeutics Market 2017-2021

Global Infantile Spasms Therapeutics Market 2017-2021

About Infantile Spasms Therapeutics

An infantile spasm is a particular type of seizure found in an epilepsy syndrome of infancy and childhood. It is also known as a West syndrome. The onset of infantile spasm is usually found in the first year of life between four months and eight months of age. The condition constitutes 2% of childhood epilepsies and 25% of epilepsies with onset in the first year of life. There are around 2,000-4,000 new cases observed in the US each year. The overall long-term prognosis for infantile spasms patients is poor. It has been found that 50%-70% of infantile spasms patients develop other seizure types and 18%-50% will develop Lennox–Gastaut syndrome (LGS) or other forms of symptomatic generalized epilepsy.

Technavio’s analysts forecast the global infantile spasms therapuetics market to grow at a CAGR of 10.16% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of infantile spasms therapuetics.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report Global Infantile Spasms Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • H. Lundbeck
  • Mallinckrodt Pharmaceuticals
  • INSYS Therapeutics
Other prominent vendors
  • Anavex Life Sciences
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals
  • ORPHELIA Pharma
  • Retrophin
  • Valerion Therapeutics
Market driver
  • Major drugs launch expected in 2017-2021
  • For a full, detailed list, view our report
Market challenge
  • Growing usage of seizure management devices, a threat to drug therapies
  • For a full, detailed list, view our report
Market trend
  • Development of devices and smartphone apps to detect seizures and track medications
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Infantile Spasms Therapeutics Market 2017-2021

Technavio recognizes the following companies as the key players in the global infantile spasms therapeutics market: H. Lundbeck, Mallinckrodt Pharmaceuticals, and INSYS Therapeutics

Other Prominent Vendors in the market are: Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, ORPHELIA Pharma, Retrophin, and Valerion Therapeutics

Commenting on the report, an analyst from Technavio’s team said: “The new trend observed in the infantile spasms market is the development of seizure alert devices that detects the seizure and notifies it to the physician, through alarms, phone calls, or text messages. SmartMonitor has developed a watch, SmartWatch, which should be worn 24 hours a day to detect any seizures. If it detects any seizures, it immediately sends out an alert warning to the caregivers/physicians. The device is now available only in the US. Also, Empatica has developed another smart watch, Embrace, which monitors the physiological stress, arousal, sleep, and physical activity of the individual. Apart from this, a smartphone application EpDetect has been developed, which exploits advanced signal processing to detect seizures. Once a seizure is detected, the application will inform the caregiver about the status of the patient along with the global positioning system (GPS) location. Similarly, BioLert has also developed EpiLert, which is an alert device with GPS and text messaging systems.”

According to the report, special regulatory designations such as fast track designations and orphan drugs designation assigned to the drugs by the US FDA and the EMA help in the faster entry of these drugs into the market. Fast track designations are assigned to the drugs used in the treatment of serious conditions with high unmet need prevailing in the market. Similarly, orphan drug designations are assigned for the drugs used in the treatment of rare diseases. These designations help in the faster approval process for the drugs and help in early entry into the market.

Further, the report states that orphan diseases such as infantile spasms disease have a lower incidence and prevalence rate than other diseases. According to the research studies published in 2015, the disease affected about one in 2,000-4,000 live births and approximately 10,000-20,000 infants were afflicted globally. Limited patient population restricts the clinical trial evaluation of drug candidates under development for the treatment of orphan indications. Drugs tested in these trials also fail to provide statistically significant results, even if they are efficacious and highly safe for consumption. Also, limited enrollment for clinical trials increases the occurrence of post-marketing adverse events. Clinical trials of new drugs and already available drugs also require large treatment populations. Drug manufacturers and researchers are also not able to recover their R&D expenses of the drugs and generate profits because of the limited patient population.

Companies Mentioned

H. Lundbeck, Mallinckrodt Pharmaceuticals, INSYS Therapeutics, Anavex Life Sciences, Catalyst Pharmaceuticals, GW Pharmaceuticals, ORPHELIA Pharma, Retrophin, Valerion Therapeutics.

  • Executive summary
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Infantile spasm: Overview
  • Market landscape
    • Global infantile spasms therapeutics market
      • Table Snapshot of global infantile spasms therapeutics market 2016
      • Table Market overview of global infantile spasms therapeutics market
      • Table Opportunity analysis in developed and emerging markets
      • Table Global infantile spasm therapeutics market 2016-2021 ($ millions)
      • Table Approved infantile spasms therapeutics
      • Table Key customer segments of global infantile spasms therapeutics market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by dosage form
    • Table Segmentation of global infantile spasms therapeutics market by dosage form
    • Solid
    • Liquid
  • Market segmentation by ROA
    • Table Segmentation of global infantile spasms therapeutics market by ROA
    • Oral
    • Parenteral
      • Table Market share of global infantile spasms therapeutics market by ROA
  • Geographical segmentation
    • Table Snapshot of global infantile spasms therapeutics market by geography
    • Table Global infantile spasms therapeutics market segmentation by geography 2016-2021 ($ millions)
    • Infantile spasms therapeutics market in Americas
      • Table Overview of infantile spasms therapeutics disease market in Americas
      • Table Market scenario in Americas
      • Table Healthcare system in US: Before and after reforms in ACA
      • Table Orphan drug development and regulatory challenges in America
      • Table Incentives provided for orphan drugs by US regulation
      • Table Infantile spasms therapeutics disease market in Americas 2016-2021 ($ millions)
    • Infantile spasms therapeutics market in EMEA
      • Table Overview of infantile spasms therapeutics market in EMEA
      • Table Percentage share of epilepsy drugs market in EMEA by geography 2015
      • Table Market scenario in EMEA
      • Table Incentives provided for orphan drugs by EU regulation
      • Table Infantile spasms therapeutics market in EMEA 2016-2021 ($ millions)
    • Infantile spasms therapeutics market in APAC
      • Table Overview of infantile spasms market in APAC
      • Table Market scenario in APAC
      • Table Incentives provided for orphan drugs by Japanese regulation
      • Table Incentives provided for orphan drugs by Australian regulation
      • Table Infantile spasms therapeutics market in APAC 2016-2021 ($ millions)
  • Market drivers
    • Major drugs launch expected in 2017-2021
      • Table CP-115 target indications
      • Table Clinical trial information for cannabidiol
    • Growing scientific advancements in diagnostics
    • Special regulatory designations
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Growing usage of seizure management devices, a threat to drug therapies
    • Limited patient population
    • Moderate pipeline
      • Table Pipeline for infantile spasms therapeutics market
      • Table Pipeline molecules being developed for the treatment of infantile spasms disease
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Impact of trends in global infantile spasms therapeutics market
    • Development of devices and smartphone apps to detect seizures and track medications
    • Alternate drugs fill the gap
    • Reformulation of marketed drugs
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global infantile spasm therapeutics market 2016
      • Table Geographical presence of key vendors
    • Other prominent vendors
  • Key vendor analysis
    • H. Lundbeck
      • Table H. Lundbeck: Key highlights
      • Table H. Lundbeck: Strength assessment
      • Table H. Lundbeck: Strategy assessment
      • Table H. Lundbeck: Opportunity assessment
    • Mallinckrodt Pharmaceuticals
      • Table Mallinckrodt Pharmaceuticals: Profile
      • Table Mallinckrodt Pharmaceuticals: Strength assessment
      • Table Mallinckrodt Pharmaceuticals: Strategy assessment
      • Table Mallinckrodt Pharmaceuticals: Opportunity assessment
    • INSYS Therapeutics
      • Table INSYS Therapeutics: Key highlights
      • Table INSYS Therapeutics: Strength assessment
      • Table INSYS Therapeutics: Strategy assessment
      • Table INSYS Therapeutics: Opportunity assessment
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report